<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04335383</url>
  </required_header>
  <id_info>
    <org_study_id>38RC20.048</org_study_id>
    <secondary_id>2020-A00311-38</secondary_id>
    <nct_id>NCT04335383</nct_id>
  </id_info>
  <brief_title>Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies</brief_title>
  <acronym>ABAC-IBS</acronym>
  <official_title>Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies From B Lymphocytes of Patients Who Have Been Followed for Infection or Colonization With Pseudomonas Aeruginosa: a Prospective Monocentric Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pseudomonas aeruginosa is a pathogenic bacteria for human, especially in hospital settings.
      It can sometimes be multi-resistant to many or even to all antibiotics usually used for its
      treatment.

      The aim of the study is to isolate and produce therapeutic antibodies against the bacteria
      Pseudomonas aeruginosa in order to provide an alternative treatment to antibiotics in case of
      infection with an antibiotic-resistant strain of Pseudomonas aeruginosa.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Isolation of recombinant human monoclonal antibodies against Pseudomonas aeruginosa</measure>
    <time_frame>1 day</time_frame>
    <description>Detection of binding of recombinant antibodies to Pseudomonas aeruginosa target proteins by ELISA assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Isolation of functional antibodies against Pseudomonas aeruginosa</measure>
    <time_frame>1 day</time_frame>
    <description>Percentage of inhibition of Pseudomonas aeruginosa infection by antibodies using an in vitro model of cell infection and virulence. Percentage of lysis of Pseudomonas aeruginosa in the presence of recombinant IgG, complement and macrophages in an opsonophagocytosis assay</description>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pseudomonas Aeruginosa</condition>
  <condition>Multi-antibiotic Resistance</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Isolation of anti-Pseudomonas antibodies from type B lymphocytes</intervention_name>
    <description>Blood sampling. Isolation of mononuclear cells from human peripheral blood by density gradient centrifugation. Identification of functional anti-Pseudomonas antibodies by ELISA and cellular infection assays.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient previously infected or colonized by Pseudomonas aeruginosa with serum containing
        functional anti-Pseudomonas aeruginosa antibodies
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient selected in the retrospective part of the study (patient with serum containing
             functional anti-Pseudomonas aeruginosa antibodies)

          -  Patient with weight ≥ 32kg.

          -  With a follow-up visit at Grenoble University Hospital with a blood sampling for its
             care

          -  Having given its written no objection to participate in the prospective phase of this
             project

        Exclusion Criteria:

          -  Legally protected patient (minor, pregnant or nursing woman, ward or ward curated,
             hospitalized under duress or deprived of liberty)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvan CASPAR, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yvan CASPAR, Dr</last_name>
    <phone>+33 4 76 76 54 79</phone>
    <email>ycaspar@chu-grenoble.fr</email>
  </overall_contact>
  <reference>
    <citation>DiGiandomenico A, Sellman BR. Antibacterial monoclonal antibodies: the next generation? Curr Opin Microbiol. 2015 Oct;27:78-85. doi: 10.1016/j.mib.2015.07.014. Epub 2015 Aug 25. Review.</citation>
    <PMID>26302478</PMID>
  </reference>
  <reference>
    <citation>Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA, Foster S, Gilmore BF, Hancock RE, Harper D, Henderson IR, Hilpert K, Jones BV, Kadioglu A, Knowles D, Ólafsdóttir S, Payne D, Projan S, Shaunak S, Silverman J, Thomas CM, Trust TJ, Warn P, Rex JH. Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect Dis. 2016 Feb;16(2):239-51. doi: 10.1016/S1473-3099(15)00466-1. Epub 2016 Jan 13. Review.</citation>
    <PMID>26795692</PMID>
  </reference>
  <reference>
    <citation>Rappuoli R, Bottomley MJ, D'Oro U, Finco O, De Gregorio E. Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. J Exp Med. 2016 Apr 4;213(4):469-81. doi: 10.1084/jem.20151960. Epub 2016 Mar 28. Review.</citation>
    <PMID>27022144</PMID>
  </reference>
  <reference>
    <citation>Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD; Protocol G Principal Investigators, Koff WC, Wilson IA, Burton DR, Poignard P. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011 Sep 22;477(7365):466-70. doi: 10.1038/nature10373.</citation>
    <PMID>21849977</PMID>
  </reference>
  <reference>
    <citation>Holzlöhner P, Hanack K. Generation of Murine Monoclonal Antibodies by Hybridoma Technology. J Vis Exp. 2017 Jan 2;(119). doi: 10.3791/54832.</citation>
    <PMID>28117810</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pseudomonas aeruginosa</keyword>
  <keyword>monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudomonas Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

